ABBV (AbbVie) Inventory-to-Revenue (2024)

What is AbbVie Inventory-to-Revenue?

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. AbbVie's Average Total Inventories for the quarter that ended in Mar. 2024 was $4,172 Mil. AbbVie's Revenue for the threemonths ended in Mar. 2024 was $12,310 Mil. AbbVie's Inventory-to-Revenue for the quarter that ended in Mar. 2024 was 0.34.

AbbVie's Inventory-to-Revenue for the quarter that ended in Mar. 2024 increased from Dec. 2023 (0.28) to Dec. 2023 (0.34)

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. AbbVie's Days Inventory for the three months ended in Mar. 2024 was 92.99.

Inventory Turnover measures how fast the company turns over its inventory within a year. AbbVie's Inventory Turnover for the quarter that ended in Mar. 2024 was 0.98.

AbbVie Inventory-to-Revenue Historical Data

The historical data trend for AbbVie's Inventory-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AbbVie Inventory-to-Revenue Chart

AbbVie Annual Data
TrendDec14Dec15Dec16Dec17Dec18Dec19Dec20Dec21Dec22Dec23
Inventory-to-Revenue
Get a 7-Day Free Trial0.05 0.06 0.06 0.06 0.07
AbbVie Quarterly Data
Jun19Sep19Dec19Mar20Jun20Sep20Dec20Mar21Jun21Sep21Dec21Mar22Jun22Sep22Dec22Mar23Jun23Sep23Dec23Mar24
Inventory-to-RevenueGet a 7-Day Free Trial0.30 0.28 0.29 0.28 0.34

Competitive Comparison of AbbVie's Inventory-to-Revenue

For the Drug Manufacturers - General subindustry, AbbVie's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AbbVie's Inventory-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AbbVie's Inventory-to-Revenue distribution charts can be found below:

* The bar in red indicates where AbbVie's Inventory-to-Revenue falls into.


AbbVie Inventory-to-Revenue Calculation

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

AbbVie's Inventory-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Inventory-to-Revenue (A: Dec. 2023 )
=Average Total Inventories / Revenue
=( (Total Inventories (A: Dec. 2022 ) + Total Inventories (A: Dec. 2023 )) / count ) / Revenue (A: Dec. 2023 )
=( (3579 + 4099) / 2 ) / 54318
=3839 / 54318
=0.07

AbbVie's Inventory-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Inventory-to-Revenue (Q: Mar. 2024 )
=Average Total Inventories / Revenue
=( (Total Inventories (Q: Dec. 2023 ) + Total Inventories (Q: Mar. 2024 )) / count ) / Revenue (Q: Mar. 2024 )
=( (4099 + 4245) / 2 ) / 12310
=4172 / 12310
=0.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AbbVie(NYSE:ABBV) Inventory-to-Revenue Explanation

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

More Related Terms:

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

AbbVie's Days Inventory for the threemonths ended in Mar. 2024 is calculated as:

Days Inventory=Average Total Inventories (Q: Mar. 2024 )/Cost of Goods Sold (Q: Mar. 2024 )*Days in Period
=4172/4094*365 / 4
=92.99

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

AbbVie's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Mar. 2024 ) / Average Total Inventories (Q: Mar. 2024 )
=4094 / 4172
=0.98

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AbbVie Inventory-to-Revenue Related Terms

Thank you for viewing the detailed overview of AbbVie's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

AbbVie (AbbVie) Business Description

Industry

GURUFOCUS.COM »STOCK LIST »Healthcare » Drug Manufacturers » AbbVie Inc (NYSE:ABBV) » Definitions » Inventory-to-Revenue

Comparable Companies

MRK PFE JNJ AMGN BMY GILD BIIB OGN SCLX AMRN LLY XSWX:ROG LSE:AZN XSWX:NOVN XPAR:SAN LSE:GSK TSE:4568 TSE:4519 XTER:BAYN SHSE:600276

Traded in Other Exchanges

ABBV:Mexico 1ABBV:Italy 4ABd:UK 0QCV:UK 4AB0:Germany 4AB:Germany 4AB:Germany 4AB:Germany ABBV:Canada ABBV34:Brazil ABBV:Austria

Address

1 North Waukegan Road, North Chicago, IL, USA, 60064-6400

AbbVie is a pharmaceutical firm with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.

Executives

Nicholas Donoghoeofficer: SVP, Enterprise Innovation1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Susan E Quaggindirector1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Jennifer L. Davisdirector1 PROCTER & GAMBLE PLAZA, CINCINNATI OH 45202
Richard A Gonzalezofficer: Chairman of the Board and CEO1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Elaine K. Sorgofficer: Sr. V.P., U.S. Commercial Ops.1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Perry C Siatisofficer: EVP, GC and Secretary1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Jeffrey Ryan Stewartofficer: SVP, US Commercial Operations1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Kevin K Buckbeeofficer: SVP, Controller1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Scott T Reentsofficer: SVP, Chief Financial Officer1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Azita Saleki-gerhardtofficer: SVP, Operations1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Carrie C Stromofficer: SVP & Pres Global Allerg Aesth1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Roxanne S Austindirector200 N SEPULVEDA BLVD, PO BOX 956 MS ES/001/A102, EL SEGUNDO CA 90245
Timothy J. Richmondofficer: EVP, Chief HR Officer1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Michael Severinoofficer: EVP, R&D and CSO1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Henry O Gosebruchofficer: Chief Strategy Officer1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064-6092

AbbVie (AbbVie) Headlines

From GuruFocus

Abbvie Inc at Wolfe Research Healthcare Conference Transcript

By GuruFocus Research 01-22-2024

Abbvie Inc at JPMorgan Healthcare Conference (Virtual) Transcript

By GuruFocus Research 01-22-2024

Abbvie Inc To Acquire Cerevel Therapeutics Transcript

By GuruFocus Research 01-22-2024

Q1 2022 Abbvie Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Abbvie Inc at Cowen Health Care Conference Transcript

By GuruFocus Research 01-22-2024

Q4 2021 Abbvie Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Abbvie Inc at Wolfe Research Healthcare Conference (Virtual) Transcript

By GuruFocus Research 01-22-2024

Q4 2022 Abbvie Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Abbvie Inc at Evercore ISI HealthCONx Virtual Conference Transcript

By GuruFocus Research 01-22-2024

Q2 2022 Abbvie Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

ABBV (AbbVie)  Inventory-to-Revenue (2024)
Top Articles
Latest Posts
Article information

Author: Delena Feil

Last Updated:

Views: 6654

Rating: 4.4 / 5 (65 voted)

Reviews: 80% of readers found this page helpful

Author information

Name: Delena Feil

Birthday: 1998-08-29

Address: 747 Lubowitz Run, Sidmouth, HI 90646-5543

Phone: +99513241752844

Job: Design Supervisor

Hobby: Digital arts, Lacemaking, Air sports, Running, Scouting, Shooting, Puzzles

Introduction: My name is Delena Feil, I am a clean, splendid, calm, fancy, jolly, bright, faithful person who loves writing and wants to share my knowledge and understanding with you.